X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PSX-001 (psilocybin) reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors. It is being evaluated in phase 2 clinical trials for the treatment of patients with generalised anxiety disorder.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: PSX-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2024
Details:
IHL-675A is Incannex’s proprietary combination product containing cannabidiol (‘CBD’) and hydroxychloroquine sulfate (‘HCQ’) for treatment of inflammatory disorders including rheumatoid arthritis.
Lead Product(s): Cannabidiol,Hydroxychloroquine Sulphate
Therapeutic Area: Immunology Product Name: IHL-675A
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2023
Details:
Fortrea will manage Incannex's IND opening Phase 2/3 clinical trial investigating IHL-42X which is a synergistic composition of dronabinol, a synthetic form of Tetrahydrocannabinol, and acetazolamide, a carbonic anhydrase inhibitor, for treatment of obstructive sleep apnoea.
Lead Product(s): Acetazolamide,Tetrahydrocannabinol
Therapeutic Area: Sleep Product Name: IHL-42X
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Fortrea
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 18, 2023
Details:
IHL-675A is Incannex’s proprietary combination product containing cannabidiol (‘CBD’) and hydroxychloroquine sulfate (‘HCQ’) for treatment of inflammatory disorders including rheumatoid arthritis.
Lead Product(s): Cannabidiol,Hydroxychloroquine Sulphate
Therapeutic Area: Immunology Product Name: IHL-675A
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2023
Details:
IHL-675A is a fixed dose combination of cannabidiol and hydroxychloroquine. It is being investigated for rheumatoid arthritis, inflammatory bowel disease and lung inflammation.
Lead Product(s): Cannabidiol,Hydroxychloroquine Sulphate
Therapeutic Area: Immunology Product Name: IHL-675A
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2023
Details:
PSI-GAD (psilocybin) reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which in turn mediates its anti-depressant and anti-anxiety effects.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Catalent Pharma Solutions
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Details:
IHL-216A (cannabidiol) is a CB1 receptor negative allosteric modulator. It is being evaluated in preclinical studies in combination with Isoflurane for the treatment of traumatic brain injury & concussion.
Lead Product(s): Cannabidiol,Isoflurane
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: IHL-216A
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
IHL-216A (cannabidiol) has been observed to have a greater neuroprotective effect in a rodent model of sports concussion than CBD, and results indicate restoration of the spatial memory deficit post-concussion with IHL-216A administration.
Lead Product(s): Cannabidiol,Isoflurane
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: IHL-216A
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Curia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 02, 2022
Details:
IHL-675A is a combination cannabinoid drug comprising cannabidiol ('CBD') and hydroxychloroquine ('HCQ') in a fixed dose combination,synergistically to inhibit production of key inflammatory cytokines.
Lead Product(s): Cannabidiol,Hydroxychloroquine Sulphate
Therapeutic Area: Immunology Product Name: IHL-675A
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2022
Details:
All doses of IHL-42X (Dronabinol) reduced AHI in patients with sleep apnoea compared to baseline. This reduction was substantially greater than observed for placebo.
Lead Product(s): Tetrahydrocannabinol,Acetazolamide
Therapeutic Area: Sleep Product Name: IHL-42X
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
